Mesoblast Company Profile

22:12 EST 10th December 2018 | BioPortfolio

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

News Articles [51 Associated News Articles listed on BioPortfolio]

Mesoblast enters $50mm equity/debt agreement with NovaQuest

Mesoblast Ltd. (allogeneic off-the-shelf cell therapies) entered a $50mm financing agreement with NovaQuest Capital, which purchased $10mm of the company's shares (at a 5% premium) and provided a $40m...

Mesoblast’s stem cell therapy reduces GI bleeding in phase 2 trial

The 159-patient randomized, sham-controlled phase 2 trial in end-stage heart failure patients implanted with a LVAD showed that Mesoblast’s allogeneic cell therapy candidate MPC-150-IM achieved sign...

Mesoblast gets access to China though deal with Tasly

Through a $65 million deal, Mesoblast will expand into the Chinese market, while Tasly moves beyond its focus on traditional Chinese medicines.

Tasly In-licenses Two Cell Therapy Treatments in $90 Million Deal

China's Tasly Pharma has in-licensed China rights to two heart drugs from Mesoblast of Australia in a $90 million agreement. Tasly will develop, manufacture and sell two Mesoblast allogeneic...

Tasly pays up to $65mm for Chinese rights to Mesoblast's MPC150IM and MPC25IC cardio candidates

Tasly Pharmaceutical Co. Ltd. licensed exclusive rights in China to develop, manufacture, and commercialize Mesoblast Ltd.'s allogeneic mesenchymal precursor cell (MPC) cardiovascular disease candidat...

Mesoblast and Cartherics form partnership to develop 'off-the-shelf' CAR-T therapies for solid cancers

Mesoblast Limited today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use i...

Mesoblast heart failure cell therapy for children featured at symposium for congenital HD

(Rubenstein Associates, Inc.) Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) heart failure product candidate MPC-150-IM for use in children with hypoplastic left heart syndrome (H...

Mesoblast Appoints New Chief Financial Officer

MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, bas...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Patients under the age of 5, with a diagnosis of hypoplastic left heart syndrome (HLHS), unbalanced atrioventricular canal (uAVC), or borderline left heart who are undergoing staged LV rec...

Companies [2 Associated Companies listed on BioPortfolio]

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USADR: MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a serie...


Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology ai...

More Information about "Mesoblast" on BioPortfolio

We have published hundreds of Mesoblast news stories on BioPortfolio along with dozens of Mesoblast Clinical Trials and PubMed Articles about Mesoblast for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mesoblast Companies in our database. You can also find out about relevant Mesoblast Drugs and Medications on this site too.

Quick Search


Relevant Topics

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Corporate Database Quicklinks

Searches Linking to this Company Record